Skip to content

We are the oldest registered charity in England/Wales as well as the oldest in Scotland who are here to support those who are affected with Alpha-1 Antitrypsin Deficiency. Not only do we support those affected, their families and friends, we also bring awareness of the condition to medical professionals and the general public. Our charity is run by non-paid volunteers who are either affected by Alpha-1 or have a family member who is. We have a real passion for the charity and for supporting people who are affected, their families and friends.

We produce booklets which people can view and download digitally and even request that a set be sent to them in the post for free (UK residents only)Click here to go to our booklet area on our main website.

While we have a website (www.alpha1.uk), we created this website so that people can see news about Alpha-1 from around the world in a quick and easy way.
If you would like to ask us a question about Alpha-1, you can use the 'Contact Us' form.

Charity News

Can you help name the new Baby Bears?

Exciting news!   Alphie and Tripsy are delighted to welcome a new sister and brother to their Alpha family.  But they now need

New Board members to our charity

Alpha-1 Awareness is a charity founded and run by volunteers to help bring awareness of AATD as well as give support to those

Alpha-1 Awareness donate £10,000 to the research of a cure

Alan Wooler, David Lomas & Emma Wooler   On Monday 3rd February 2020, Alan and Emma Wooler of Alpha-1 Awareness went to UCL

Alpha-1 in the Press

New blood test predicts which COVID-19 patients will develop severe infection

18th October 2020  Professor Gerry McElvaney (left), the study’s senior author and a consultant in Beaumont Hospital, and Professor Ger Curley (right) stand

BBC documentary Surgeons: At the edge of life will show AATD patient receive a double lung transplant.

On Tuesday 20 October, the BBC documentary Surgeons: At the edge of life will show David (pictured below) receiving a double lung transplant.

Grifols begins phase 3 testing for COVID-19 treatment

  RESEARCH TRIANGLE PARK — Grifols, a global biotherapeutics company, has begun Phase 3 clinical trials in patients with COVID-19 with its therapeutic manufactured in

Other Alpha-1 Group’s News

NEW IRISH ALPHA-1 RESEARCH IN 2020

Irish Alpha-1 research published last month in “Thorax”, one of the world’s leading respiratory medicine journals, highlights the crucial importance of patient registries for

AlphaNet Announces New Appointment to the Board of Directors

AlphaNet is pleased to announce the appointment of Dell Witcher to the board of directors, effective May 14, 2020. “Dell’s expertise and involvement

Research Priorities in Alpha-1 antitrypsin deficiency (AATD)

We need your help! Being led by the European Alpha-1 Research Collaboration (EARCO), a survey has been created to give us all input

 

 

 

General Research

New blood test predicts which COVID-19 patients will develop severe infection

18th October 2020  Professor Gerry McElvaney (left), the study’s senior author and a consultant in Beaumont Hospital, and Professor Ger Curley (right) stand

Largest Source of AATD Stem Cells Collected

Researchers from the Center for Regenerative Medicine (CReM) have assembled the largest repository of patient derived stem cells (iPSCs) from patients with alpha-1

Researchers build a better lung model

(Boston)–Using a combination of pluripotent stem cells (cells that can potentially produce any cell or tissue type) and machine learning (artificial intelligence that

Treatment Research & Trials

Vertex Abandons VX-814 Program for Treating Rare Liver Disease

15th October 2020 Vertex Pharmaceuticals announced that based on early data of its Phase II trial of VX-814 in Alpha-1 antitrypsin deficiency (AATD), it is

Healthy PiMZ Alphas required for a new trial

If you are a healthy PiMZ then please consider taking part in this exciting Alpha-1 clinical trial. Please contact HMR direct using the

First subject dosed with ZF874, a potential disease-modifying treatment for alpha-1-antitrypsin deficiency

Z Factor Ltd, a Cambridge-based drug development company spun out of the University of Cambridge, announced that the first human volunteer was dosed

Treatments

Danish Medicines Council Grants Approval for CSL Behring’s Respreeza as Standard Treatment for Severe Alpha-1 Antitrypsin Deficiency Patients

HATTERSHEIM AM MAIN, Germany, Jan. 24, 2020 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the Danish Medicines Council has published its final decision,

CSL Behring lift their precautionary distribution hold on ZEMAIRA®

The Alpha-1 Foundation received the following communication update from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of

Diplomat signs exclusive practice-based infusion agreement with Allergy Partners

FLINT, Mich., Aug. 8, 2019 /PRNewswire/ — Diplomat Pharmacy, Inc. (NYSE: DPLO), is pleased to announce an exclusive agreement between Diplomat and Allergy Partners, P.A., to manage in-office

 

 

 

Help and Advice

European Lung Foundation advise on planning a flight

ELF (European Lung Foundation) has produced a poster to help make people with lung conditions aware of the steps they should take when

Other Articles

Health Benefits of Air Pollution Reduction

Reducing air pollution improves people’s health very quickly, reports a paper from the Forum of International Respiratory Societies (FIRS). Air pollution is when

Michigan becomes first state to ban flavored e-cigarettes

Michigan becomes the first state to ban flavored e-cigarettes for minors starting today. Governor Gretchen Whitmer has been making a push to get nicotine out

First U.S. death caused by vaping confirmed in Illinois

The first reported death tied to vaping in the United States was confirmed on Friday by officials from the Illinois Department of Public Health.

© 2019 Alpha-1 Awareness